Emerging drug targets for colon cancer: A preclinical assessment.

ABSTRACT:

Introduction

Colorectal cancer (CRC) is the second leading cause of cancer-related death in the United States. There have been improvements in screening, and therefore overall survival, but patients continue to present at late stages when minimal treatment options are available to them. While some targeted therapies have been introduced, their application is limited by patient-specific tumor characteristics. Additional targets for CRC in patients who present at a late stage, or who experience tumor relapse, need to be identified to continue to improve patient outcomes.

Areas covered

This review focuses on emerging pathways and drug targets for the treatment of colorectal cancer. The shift to the cancer stem cell model and potential targets involving Wnt, NF-κB, phosphodieste

SUBMITTER: Crutcher MM 

PROVIDER: S-EPMC9075542 | biostudies-literature | 2022 Mar

REPOSITORIES: biostudies-literature